Evolving Therapies in Multiple Sclerosis: BTK Inhibitors

Visit https://www.peervoice.com/HGK860 to view the entire programme with slides. After completing “Evolving Therapies in Multiple Sclerosis: BTK Inhibitors”, participants will be able to: Describe the role of Bruton's tyrosine kinase (BTK) and immune cells in multiple sclerosis (MS) pathogenesis; Explain the limitations of current B-cell therapeutic strategies and the rationale for the investigation into BTK inhibitors; Summarise the most recent clinical data for BTK inhibitors in patients with MS.